- Market Realist•6 hours ago
Incyte has classified its oncology product portfolio into targeted anti-cancer therapies and immuno-oncology or immunotherapies.
- PR Newswire•7 hours ago
INDIANAPOLIS, March 1, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced the successful completion of its acquisition of CoLucid Pharmaceuticals, Inc. (CLCD). The tender offer for all outstanding shares of common stock of CoLucid, at a price of $46.50 per share, expired as scheduled on Tuesday, February 28, 2017. As of the expiration of the tender offer, 17,410,607 shares of CoLucid common stock were validly tendered, representing approximately 90.3 percent of the shares outstanding, and have been accepted for payment under the terms of the tender offer.
- TheStreet.com•20 hours ago
Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.
LLY : Summary for Eli Lilly and Company Common St - Yahoo Finance
Eli Lilly and Company (LLY)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||82.97 - 84.14|
|52 Week Range||64.18 - 84.14|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||32.57|
|Dividend & Yield||2.08 (2.50%)|
|1y Target Est||N/A|